Whereas EIF4EBP1 and EIF4EBP3 seem to be overexpressed in gliomas, this is less clear for EIF4EBP2 as data from REMBRANDT show an increase in mRNA levels in oligodendrogliomas and astrocytomas, but not in GBM, whereas, according to the TCGA analysis, there is a decrease in EIF4EBP2 in most GBM subtypes (Table 1). This evidence concerns the gene EIF4EBP1 and central nervous system cancer.